STOCK TITAN
  1. Home
  2. News
  3. OSA

ProSomnus, Inc. - OSA STOCK NEWS

Welcome to our dedicated news page for ProSomnus (Ticker: OSA), a resource for investors and traders seeking the latest updates and insights on ProSomnus .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProSomnus 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProSomnus 's position in the market.

News
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) announced record revenues of $7.8 million for Q4 and $27.7 million for fiscal year 2023, marking an increase of 35% and 43% respectively. The company focused on expense reductions, demonstrated technical feasibility of its Next Generation Remote Patient Monitoring device, and submitted a 510(k) Premarket Notification for label expansion. Financially, revenues increased driven by precision devices adoption, sales, and marketing investments. However, cost of revenue and expenses also increased, impacting the bottom line.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
earnings
-
News
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
Rhea-AI Summary
ProSomnus, Inc. (OSA) delays 2023 Q4 and full year financial results release and investor call, rescheduled for March 26, 2024. The company also cancels attendance at the Roth Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
earnings
-
News
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) announces successful pilot study results for its Next Generation Remote Patient Monitoring device for Obstructive Sleep Apnea. The innovative device accurately monitors SpO2, paving the way for personalized and preventative sleep medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
none
News
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) will report its Q4 and fiscal year 2023 financial results and provide a business update at the 36th Annual ROTH Conference. CEO Len Liptak and CFO Brian Dow will host a conference call and participate in investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.03%
Tags
earnings
-
News
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
Rhea-AI Summary
ProSomnus, Inc. announced that the FDA has accepted its premarket notification for the ProSomnus EVO precision medical device for the treatment of severe obstructive sleep apnea. The clinical data submitted by the Company demonstrated significant improvements in patients' AHI, ODI, and sleep apnea specific hypoxic burden without patient preselection or excluding patients with concentric collapse airway profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
none
-
News
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
Rhea-AI Summary
ProSomnus, Inc. is well-positioned to support patients with Obstructive Sleep Apnea (OSA) following the discontinuation of CPAP devices by Philips Respironics. The company offers precision intraoral devices with excellent efficacy and patient preference. ProSomnus is ready to facilitate access to high-quality healthcare for millions of patients suffering from untreated OSA, providing a non-invasive and comfortable alternative to traditional CPAP therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
News
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
Rhea-AI Summary
ProSomnus, Inc. (OSA) welcomes UnitedHealthcare's updated medical policy for obstructive and central sleep apnea, which establishes oral appliance therapy as a prerequisite for Implantable Hypoglossal Nerve Stimulation. Recent research and data show that modern, precision oral appliances are effective, safe, and non-invasive, with a high level of patient satisfaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
News
Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices
Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) Successfully Treats OSA Patients with Precision Oral Appliance Therapy, New Clinical Research Shows
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
57.8%
Tags
none
-
News
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
Rhea-AI Summary
ProSomnus, Inc. (OSA) reports record quarterly revenue of $7.1 million, marking a 41.5% year-over-year increase and seventh consecutive quarter of sequential revenue growth. The company also achieved a 45.7% increase in revenues for the nine months ended 2023. ProSomnus continues to advance in clinical studies and achieved 13485:2016 Certification from Intertek.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
earnings
News
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
Rhea-AI Summary
ProSomnus, Inc. (NASDAQ: OSA) will report its third quarter financial results on November 9, 2023. The conference call will be hosted by CEO Len Liptak and CFO Brian Dow at 1:30 pm PT / 4:30 pm ET. Interested parties can register for the conference call and access the live webcast through the ProSomnus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
earnings
Stock OSA logo
ProSomnus, Inc.

Nasdaq:OSA

OSA Rankings

N/A Ranked by Market Cap
#5489 Ranked by Stock Gains
N/A Ranked by Dividends

OSA Stock Data

8.18M
8.09M
20.64%
57.01%
0.42%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
PLEASANTON